Triple agonists combining GLP 1, GIP and glucagon receptor activity represent another frontier with early data suggesting these may produce even greater weight loss and metabolic improvements
[3] However, in a promising transition for all metabolic health stakeholders, the treatment landscape is likely to drastically shift with generic GLP-1 receptor agonists (GLP-RAs) becoming available in India for the first time, marking a meaningful change in access for a class that was, until recently, out of reach for most patients
Building long-term eating habits beyond GLP-1 GLP-1 therapy is not permanent for most people
The blend is administered via subcutaneous injection, typically before bed to align with natural GH secretion patterns
We work with patients to find solutions
The side effects of hGH are stark, but because of how sermorelin stimulates hGH, it avoids some of those side effects